R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter prospective single arm phase Ib/II study, and the purpose of this study
is to evaluate the safety and efficiency of R2-MTX regimen (rituximab & lenalidomide &
methotrexate) combined with lenalidomide maintenance in newly-diagnosed primary central
nervous system lymphoma. 2-year Progression free survival (PFS) of the cohort is the primary
endpoint.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Beijing Hospital Beijing Tiantan Hospital Chinese PLA General Hospital Peking University First Hospital Peking University Third Hospital Xuanwu Hospital, Beijing